Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development

PR Newswire February 3, 2022

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

PR Newswire January 20, 2022

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

PR Newswire January 7, 2022

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia

PR Newswire December 22, 2021

Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

PR Newswire December 20, 2021

Syndax Announces Pricing of $75.3 Million Public Offering

PR Newswire December 15, 2021

Syndax Announces Proposed Public Offering of Common Stock

PR Newswire December 15, 2021

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

PR Newswire December 13, 2021

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

PR Newswire December 11, 2021

Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab

PR Newswire December 9, 2021

Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update

PR Newswire November 15, 2021

Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021

PR Newswire November 8, 2021

Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting

PR Newswire November 4, 2021

Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

PR Newswire September 27, 2021

Syndax Appoints Martin H. Huber, M.D., to its Board of Directors

PR Newswire September 15, 2021

Syndax Announces Participation at Three Upcoming Investor Conferences

PR Newswire September 2, 2021

Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update

PR Newswire August 9, 2021

Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

PR Newswire August 2, 2021

SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias

PR Newswire June 28, 2021

Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

PR Newswire June 3, 2021